Cartalax

Mechanism of Action

Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts.

Step 1 - Tissue distribution. At ~446.5 daltons (H-Ala-Glu-Asp-Leu-OH), Cartalax is small and polar enough to cross phospholipid bilayers passively. Khavinson-group tritiated-peptide biodistribution work (Russian-language literature) describes rapid tissue uptake across cartilage, liver, kidney, and other organs after intraperitoneal or oral administration. Cartilage's unique tissue architecture - avascular, low cellularity with chondrocytes embedded in dense extracellular matrix - raises questions about how efficiently any systemic peptide reaches chondrocyte nuclei. The biodistribution data do not distinguish intact peptide from catabolite signal and do not quantify chondrocyte-level uptake.

Step 2 - Chondrocyte targeting. The Khavinson-framework claim is that AEDL reaches chondrocyte nuclei and modulates chromatin in a cartilage-specific manner. No structural biology, no chondrocyte-specific transcriptomic data, and no modern target validation has been published. The mechanistic claim rests on extrapolation from the bioregulator framework.

Step 3 - Chromatin modulation of chondrocyte programmes. The framework hypothesises that AEDL increases type II collagen synthesis and aggrecan deposition in chondrocytes and attenuates IL-1-induced MMP-13 upregulation, via preferential activation of chondrogenic transcription factors (SOX9, RUNX2 balance) and anti-catabolic chromatin states. This is a hypothesis, not a demonstrated result: no peer-reviewed chondrocyte study of Cartalax is indexed in PubMed. Modern chondrocyte biology uses iPSC-derived chondrocytes, single-cell RNA-seq of cartilage biopsy samples, and CRISPR-based target validation - none of which has been applied to Cartalax.

Alternative conservative framing. A parsimonious interpretation treats Cartalax as an amino-acid source delivering alanine, glutamate, aspartate, and leucine in a rapidly hydrolysed peptide form. Under this framing, biological effects could reflect: (a) leucine-mediated mTOR activation supporting chondrocyte protein synthesis (leucine is a classical mTORC1 trigger with well-characterised kinetics), (b) glutamate/aspartate substrate delivery for TCA cycle anaplerosis in chondrocytes, (c) non-specific amino acid nutritional support. If this framing is correct, leucine supplementation (or branched-chain amino acid mixtures) at far lower cost would produce equivalent effects.

Comparison to glucosamine, chondroitin, and collagen peptides. Glucosamine and chondroitin sulphate have been tested in multiple RCTs for osteoarthritis with heterogeneous results - some showing modest symptomatic benefit, others showing no effect above placebo (e.g., the GAIT trial). Collagen hydrolysate peptides (2.5-10 g daily) have small-effect-size positive evidence for OA symptoms, particularly in the knee. Undenatured type II collagen (UC-II) 40 mg daily has small but positive trial data for knee OA. Cartalax sits at a fundamentally different level of specification - hypothesis about chromatin rather than biochemical substrate provision. If Cartalax works purely through amino-acid supplementation, it is inferior to collagen peptides (which provide far more amino acid mass) on cost-effectiveness grounds.

Comparison to BPC-157 and TB-500. Among peptide options for cartilage and tendon, BPC-157 and TB-500 have substantially more mechanistic and pre-clinical data in English-indexed literature - BPC-157 with documented angiogenesis and tendon-healing effects, TB-500 with actin-sequestering mechanism and regenerative claims. Neither is FDA-approved or RCT-validated in humans, but both have better-characterised mechanism than Cartalax. In peptide-community hierarchies for connective tissue support, BPC-157 and TB-500 typically rank above Khavinson tetrapeptides.

Receptor pharmacology. No GPCR, nuclear receptor, or defined enzyme target identified for Cartalax. It does not engage the IL-1 or TNF pathways directly. It does not inhibit COX-1, COX-2, or LOX. It does not bind cartilage-specific receptors. The absence of a defined pharmacological target is characteristic of the Khavinson framework.

Relation to Sygumir and cartilage polypeptide extracts. Cartalax is a synthetic defined-sequence analogue to bovine or porcine cartilage polypeptide extracts sold under various names in post-Soviet supplement channels. Both are positioned as "cartilage bioregulators"; Cartalax is the chemically characterised short peptide while extracts are undefined mixtures. Whether the synthetic tetrapeptide recapitulates extract bioactivity is the open question.

Overall. Cartalax is a hypothesis-level peptide. Mechanism claims are not validated by modern techniques. If the clinical goal is joint and cartilage support, evidence-graded interventions (weight management, exercise, NSAIDs, collagen peptides, possibly BPC-157/TB-500 with more data) are substantially better-supported.

Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, and Cardiogen within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme.

Outside Russia, Cartalax is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises in vitro chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis ([Khavinson et al., 2011]; [Chalisova et al., 2014]; [Anisimov et al., 2010]).

The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy.

BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin and Boswellia for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 and TB-500 as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy.

IUPAC Name

L-Alanyl-L-glutamyl-L-aspartyl-L-serine

CAS Number

Not yet available

Molecular Formula

Ala-Glu-Asp-Ser

Molecular Mass

446.5 g/mol

Unlock the dosing protocols

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

• Dose, how often and how long
• Beginner, intermediate and advanced protocols
• Reconstitution and handling notes
• Stacking notes

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Unlock the research summary

Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

• A summary of the key research
• Safety and side effects
• A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

Interaction Matrix

Related Compounds

Related Articles

Disguised Alpha

$49.99($2.50/mg)

Data Completeness

COA Verification

Research Volume